Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.

Pharmacogenetics - 1 Feb 2000

Wadelius M, Stjernberg E, Wiholm B E, Rane A

Abstract excerpt

Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine. The polymorphic enzyme N-acetyltransferase 2 (NAT2) plays an important role in the metabolism of sulphasalazine. This study was conducted to analyse whether the risk of sulphasalazine-induced agranulocytosis is increased in slow acetylators. Patients were treated for inflammatory disease, mostly joint disease, with a mean dose of 2 g...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Arthritis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Granulocytes

Share to Inflammatory Bowel Diseases

Share to Leukocyte Count

Share to Risk Assessment

Source

Identifiers

PMID: 10739170
DOI: 10.1097/00008571-200002000-00005

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.PMID 10739170Read ↗

Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.Semantic proximity Read ↗

Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.Semantic proximity Read ↗

NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus.Semantic proximity Read ↗

N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.Semantic proximity Read ↗

Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.Semantic proximity Read ↗

N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.Semantic proximity Read ↗

A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.Semantic proximity Read ↗

Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.Semantic proximity Read ↗

Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.Semantic proximity Read ↗

Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.